Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.
Sign Up to like & getrecommendations! Published in 2019 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2019.1847
Abstract: Importance Erlotinib is a standard first-line therapy for patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). Median progression-free survival (PFS) with erlotinib is approximately 10 months. Objective To determine whether adding… read more here.
Keywords: pfs; egfr mutant; trial; erlotinib ... See more keywords
Time-staggered delivery of erlotinib and doxorubicin by gold nanocages with two smart polymers for reprogrammable release and synergistic with photothermal therapy.
Sign Up to like & getrecommendations! Published in 2019 at "Biomaterials"
DOI: 10.1016/j.biomaterials.2019.119327
Abstract: Photochemotherapy is currently an effective anticancer therapy. Recently, it has been reported that cancer cells pretreated with epidermal growth factor receptor (EGFR) inhibitor erlotinib (Erl) can significantly synergize its apoptosis against the DNA damaging agent… read more here.
Keywords: time staggered; erlotinib; therapy; photothermal therapy ... See more keywords
Physical blood‐brain barrier disruption induced by focused ultrasound does not overcome the transporter‐mediated efflux of erlotinib
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Controlled Release"
DOI: 10.1016/j.jconrel.2018.11.009
Abstract: &NA; Overcoming the efflux mediated by ATP–binding cassette (ABC) transporters at the blood‐brain barrier (BBB) remains a challenge for the delivery of small molecule tyrosine kinase inhibitors (TKIs) such as erlotinib to the brain. Inhibition… read more here.
Keywords: disruption; fus; erlotinib; bbb disruption ... See more keywords
Polymorphs and hydrates of the anticancer drug erlotinib: X-ray crystallography, phase transition and biopharmaceutical studies
Sign Up to like & getrecommendations! Published in 2021 at "CrystEngComm"
DOI: 10.1039/d1ce00032b
Abstract: Erlotinib, a non-small cell lung cancer BCS class II drug, was found to occur as two polymorphs and two hydrates depending on the crystallization conditions. The monohydrate (form III), which has been reported in patents… read more here.
Keywords: form; polar solvents; form iii; erlotinib ... See more keywords
Sensitivity of non-small cell lung cancer to erlotinib is regulated by the Notch/miR-223/FBXW7 pathway
Sign Up to like & getrecommendations! Published in 2017 at "Bioscience Reports"
DOI: 10.1042/bsr20160478
Abstract: Recent evidence supports a role for microRNA-223 (miR-223) in modulating tumor cell sensitivity to chemotherapeutic drugs; however, its role in cellular resistance to the effects of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) used… read more here.
Keywords: hcc827 cells; hcc827; erlotinib; expression ... See more keywords
Multifunctional magnetic nanoparticles for MRI-guided co-delivery of erlotinib and L-asparaginase to ovarian cancer
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Microencapsulation"
DOI: 10.1080/02652048.2022.2094487
Abstract: Abstract The use of magnetic nanoparticles (MNPs) in biomedical applications has been wildly opted due to their unique properties. Here, we designed MNPs loaded with erlotinib (ERL/SPION-Val-PEG) and conjugated them with anti-mucin16 (MUC16) aptamer to… read more here.
Keywords: ovarian cancer; asparaginase; erlotinib; magnetic nanoparticles ... See more keywords
TRPV3 Mutation‐Associated Olmsted Syndrome in a Hispanic Patient: Response to Erlotinib and Review of Literature
Sign Up to like & getrecommendations! Published in 2025 at "Pediatric Dermatology"
DOI: 10.1111/pde.15892
Abstract: Olmsted syndrome (OS) is a rare genetic condition characterized by severe palmoplantar and periorificial keratoderma, often linked to TRPV3 gene mutations. This case report describes a 23‐month‐old Hispanic boy with TRPV3‐associated OS who initially showed… read more here.
Keywords: mutation associated; erlotinib; review literature; olmsted syndrome ... See more keywords
Identification of Ketene-Reactive Intermediate of Erlotinib Possibly Responsible for Inactivation of P450 Enzymes
Sign Up to like & getrecommendations! Published in 2018 at "Drug Metabolism and Disposition"
DOI: 10.1124/dmd.117.079327
Abstract: Erlotinib (ELT), a tyrosine kinase inhibitor, is widely used for the treatment of nonsmall cell lung cancer in clinic. Unfortunately, severe drug-induced liver injury and other adverse effects occurred during the treatment. Meanwhile, ELT has… read more here.
Keywords: inactivation; erlotinib; p450; intermediate ... See more keywords
Abstract 5958: Exploring AKR1C3 as a therapeutic target to overcome erlotinib resistance in lung adenocarcinoma
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/1538-7445.am2024-5958
Abstract: Introduction: Erlotinib has demonstrated promising efficacy in lung adenocarcinoma (LUAD) patients with epidermal growth factor receptor mutation. However, the development of resistance to erlotinib poses a significant challenge in achieving long-lasting treatment responses. Aldo-keto reductase… read more here.
Keywords: resistance; erlotinib resistance; erlotinib; tumor ... See more keywords
Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations: NEJ026.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.9006
Abstract: 9006Background: Development of treatment for EGFR-mutated non-small-cell lung cancer (NSCLC) had been focused on monotherapy of gefitinib, erlotinib, or afatinib. Combinations of EGFR-TKIs and VEGF inhibitors are one of candidates for next strategy for EGFR-mutated… read more here.
Keywords: egfr mutations; study comparing; erlotinib; phase iii ... See more keywords
A phase II randomized control trial of erlotinib in combination with celecoxib in patients with operable oral squamous cell carcinoma (OSCC): Erlo-Xib Study.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.6054
Abstract: 6054 Background: When combined with COX-2 inhibitors, the EGFR tyrosine kinase inhibitor Erlotinib has shown a better antitumor response in preclinical studies. Since high volume hospitals in many countries usually have a longer waiting period… read more here.
Keywords: oral squamous; combination; treatment; erlotinib ... See more keywords